Comparative study on government subsidy models for competitive drug supply chains under centralized procurement policy.

ABSTRACT: As the generic drug market tends to be saturated, the structural transformation of generic drug companies is imminent, while the high investment and high-risk attributes of innovative drug research and development aggravate the transformation difficulties. Against the backdrop of drug centralized procurement policy, considering the effect of health insurance reimbursement and market competition ferocity, this study constructs a differential game model of a secondary drug supply chain comprising two competing drug companies and a single healthcare institution. In addition, this study comparatively analyzes the optimal equilibrium strategies and supply chain profit levels of drug research and development investment and healthcare service efforts under four government subsidy modes, further d

SUBMITTER: Wen Y 

PROVIDER: S-EPMC11949922 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature